Hosted on MSN45m
Regeneron Culls Losses After High-Dose Eylea Sales DisappointRegeneron stock fell slightly Monday after the drugmaker preannounced light sales of a high-dose version of eye drug Eylea.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback